Bacil Pharma Ltd.
BSE: 524516 | Sector: Health care |
NSE: N.A. | ISIN Code: INE711D01018 |
BSE 10:27 | 20 May | 4.57 |
0 (0.00%) |
OPEN
4.70 |
HIGH
4.70 |
LOW
4.57 |
NSE 05:30 | 01 Jan | Bacil Pharma Ltd |
OPEN | 4.70 |
PREVIOUS CLOSE | 4.57 |
VOLUME | 120 |
52-Week high | 9.55 |
52-Week low | 3.67 |
P/E | |
Mkt Cap.(Rs cr) | 3 |
Buy Price | 4.57 |
Buy Qty | 199.00 |
Sell Price | 0.00 |
Sell Qty | 0.00 |
Bacil Pharma Ltd. (BACILPHARMA) - Latest News & Headlines
-
Bacil Pharma Ltd Submission Of Certificate As Per Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requir
15/04/2022 | bse |
Downlaod PDF
-
Bacil Pharma Ltd Format of Initial Disclosure to be made by an entity identified as a Large Corporate
14/04/2022 | bse |
Downlaod PDF
-
Bacil Pharma Ltd Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
14/04/2022 | bse |
Downlaod PDF
-
Bacil Pharma Ltd Reg. 7(3) -Compliance Certificate For The Year Ended 31St March 2022
13/04/2022 | bse |
Downlaod PDF
-
Bacil Pharma Ltd Closure of Trading Window
31/03/2022 | bse |
Downlaod PDF
-
Ruchi Soya acquires Patanjali Ayurved's food business for Rs 690 crore
1.32 am | 19 May 2022 | Business Standard
To pay 1% of turnover of products as annual royalty under transfer agreement
-
Ruchi Soya hits upper circuit on buyout of Patanjali's food retail business
3.58 pm | 18 May 2022 | Business Standard
The board also approved to change company's name from Ruchi Soya Industries to Patanjali Foods.
-
Gokaldas Exports surges 9%; hits all-time high on healthy business outlook
10.17 am | 18 May 2022 | Business Standard
A shift in consumer preferences post pandemic towards wovens, as people seek more formal clothes, may improve demand.
-
UltraTech, JSW lost Ambuja race due to CCI concerns: Holcim CEO
1.44 am | 18 May 2022 | Business Standard
The CEO said the smoothness of the execution of such a transaction was a major factor in taking the decision.
-
Street betting on revival of metals cycle amid buzz of over-correction
11.42 pm | 17 May 2022 | Business Standard
High input costs leading to margin pressure, lower-than-expected realisations are among downside risks
Quick Links for Bacil Pharma:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices